Market Overview:
Factor IX deficiency is a rare bleeding disorder that affects males and females equally. It is caused by a lack of clotting factor IX, a protein in the blood that helps it to clot. There are two types of factor IX deficiency: hemophilia B and Christmas disease. Hemophilia B is the most common type, accounting for about 80% of all cases. Factor IX deficiency can lead to uncontrolled bleeding, which can cause serious health problems if not treated properly. The global market for Factor IX Deficiency Treatment was valued at US$ 2,848 million in 2017 and is expected to reach US$ 5,711 million by 2030 at a CAGR of 7%.
Product Definition:
Factor IX Deficiency Treatment is a medical treatment that is used to help people who have a deficiency in the factor IX protein. This treatment can help to improve their blood clotting ability and prevent bleeding episodes.
Hemophilia B:
Hemophilia B is a rare bleeding disorder caused due to decreased levels of coagulation factor IX. It’s prevalence is 1 in 5,000 males and 1 in 10,000 females. The disease mostly occurs among people of European descent. Factors such as genetic mutation and environmental factors are responsible for the condition’s development. According to the National Institute of Health (NIH), about 30,000-40,000 cases are registered each year in U.
Hemophilia B Inhibitors:
Hemophilia B Inhibitors (BFI) are a group of medications used to prevent blood clotting. They are different from other anticoagulants such as warfarin and heparin in that they work specifically on the factor IX level. The market for BFI is smaller than that of warfarin and heparin due to higher cost, more specific indications, and lower usage rates.
Application Insights:
The other application segment accounted for the largest share of factor IX deficiency treatment in 2017. Other applications include therapeutic drug monitoring and recombinant factor IX therapies. The others segment is anticipated to witness significant growth over the forecast period due to increasing adoption of these products in emerging economies such as China, India, Brazil and Mexico. In addition, factors such as rising incidences of Bleeding Disorders Association (BDA) clinics across developing countries are expected to drive demand for factor IX deficiency treatment products during the forecast period.
Hospitals were estimated as the largest revenue-generating centers owing to high prevalence rates of hemophilia and availability of a large number on an average patient with hemophilia worldwide per year since 1990s up until 2016 which was around 1,500 patients per year globally according to data published by International Society on Thrombosis and Haemostasis (ISTH).
Regional Analysis:
North America dominated the global factor IX deficiency treatment market in 2017. This can be attributed to the presence of key players, high adoption rate of new therapies, and favorable reimbursement policies. The U.S., which is one of the developed economies in North America, has a well-developed healthcare infrastructure that makes it easier for patients to access advanced treatments at various stages.
In Asia Pacific region factor IX deficiency treatment market is anticipated to witness lucrative growth over the forecast period owing to improving healthcare facilities and growing patient awareness about available treatments along with rising disposable income & standard of living especially in developing countries such as India.
The Latin American region accounted for a significant share due its large population base suffering from hemophilia B & inhibitors across Brazil.
Growth Factors:
- Increasing incidence of Factor IX deficiency
- Growing awareness about the treatment for Factor IX deficiency
- Rising demand for better and more effective therapies for the treatment of Factor IX deficiency
- Technological advancements in the field of gene therapy and recombinant technology that are expected to offer new and better treatment options for patients with Factor IX deficiency in the near future 5. Availability of government funding and support for research on novel treatments for rare diseases such as Factor IX deficiency, which is likely to spur growth in this market over the forecast period
Scope Of The Report
Report Attributes
Report Details
Report Title
Factor IX Deficiency Treatment Market Research Report
By Type
Hemophilia B, Hemophilia B Inhibitors
By Application
Hospitals, Clinics, Other
By Companies
Pfizer, Takeda, Novo Nordisk, Biogen, CSL Behring
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
156
Number of Tables & Figures
110
Customization Available
Yes, the report can be customized as per your need.
Global Factor IX Deficiency Treatment Market Report Segments:
The global Factor IX Deficiency Treatment market is segmented on the basis of:
Types
Hemophilia B, Hemophilia B Inhibitors
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- Takeda
- Novo Nordisk
- Biogen
- CSL Behring
Highlights of The Factor IX Deficiency Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Hemophilia B
- Hemophilia B Inhibitors
- By Application:
- Hospitals
- Clinics
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Factor IX Deficiency Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Factor IX deficiency is a rare blood disorder that can result in serious bleeding. Treatment typically includes regular blood transfusions to prevent death.
Some of the key players operating in the factor ix deficiency treatment market are Pfizer, Takeda, Novo Nordisk, Biogen, CSL Behring.
The factor ix deficiency treatment market is expected to grow at a compound annual growth rate of 7%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Factor IX Deficiency Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Factor IX Deficiency Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Factor IX Deficiency Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Factor IX Deficiency Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Factor IX Deficiency Treatment Market Size & Forecast, 2020-2028
4.5.1 Factor IX Deficiency Treatment Market Size and Y-o-Y Growth
4.5.2 Factor IX Deficiency Treatment Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Hemophilia B
5.2.2 Hemophilia B Inhibitors
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Clinics
6.2.3 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Factor IX Deficiency Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Factor IX Deficiency Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Hemophilia B
9.6.2 Hemophilia B Inhibitors
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Clinics
9.10.3 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Hemophilia B
10.6.2 Hemophilia B Inhibitors
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Clinics
10.10.3 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Hemophilia B
11.6.2 Hemophilia B Inhibitors
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Clinics
11.10.3 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Hemophilia B
12.6.2 Hemophilia B Inhibitors
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Clinics
12.10.3 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Hemophilia B
13.6.2 Hemophilia B Inhibitors
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Clinics
13.10.3 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Factor IX Deficiency Treatment Market: Competitive Dashboard
14.2 Global Factor IX Deficiency Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Pfizer
14.3.2 Takeda
14.3.3 Novo Nordisk
14.3.4 Biogen
14.3.5 CSL Behring
